Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1161]

ESMO 2021: Updates in hormone-sensitive prostate cancer

Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena...

ESMO 2021: Updates in hormone-sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Castro )

Quality of life and safety in novel therapies for prostate cancer

Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal

Quality of life and safety in novel therapies for prostate cancer ( Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal )

Enzalutamide plus androgen deprivation therapy prolongs survival in men with...

Prof Andrew Armstrong - Duke University, Durham, USA

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Adding abiraterone acetate plus prednisolone to standard therapy lengthens...

Prof Nick James - The Institute of Cancer Research, London, UK

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer ( Prof Nick James - The Institute of Cancer Research, London, UK )

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic...

Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of...

Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )

More from ecancer